An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients
Information source: Janssen Inc.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Human Immunodeficiency Virus (HIV)
Intervention: darunavir (PREZISTA) (Drug); etravirine (INTELENCE) (Drug); ritonavir (Drug); Other antiretroviral medications (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Janssen Inc. Official(s) and/or principal investigator(s): Janssen Inc. Clinical Trial, Study Director, Affiliation: Janssen Inc.
Summary
The purpose of this study is to evaluate tolerability of darunavir (PREZISTA) or etravirine
(INTELENCE) in patients infected with human immunodeficiency virus type 1 (HIV-1) who are
naïve to these medications and in patients who have experienced tolerability issues on their
current or prior combination antiretroviral therapy (cART). The tolerability is evaluated by
switching the patients from their previous or current combination antiretroviral therapy
(cART) to either darunavir or etravirine.
Clinical Details
Official title: PREZISTA or INTELENCE Switch Evaluation in Virologically Suppressed Patients Naïve to Darunavir or Etravirine and Who Are Intolerant of Their Current or Prior Combination Antiretroviral Therapy Regimen: A Phase IV, Open-label, Multicentre Observational Trial
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Change from Baseline in the patient's total score of the HIV Symptom Distress Module (HIV-SDM)
Secondary outcome: Number of participants with Maintenance/achievement of virologic suppression at Week 24Number of participants with disappearance by Week 4 of at least one bothersome symptom identified at baseline by patient on HIV-SDM Number of participants with maintenance of disappearance by Week 12 and Week 24 of at least one bothersome symptom identified at baseline by patient on HIV-SDM Number of participants with Maintenance/increase in CD4 cell count. Comparison of change in HIV-SDM scores between those participants who were on or off ARTs at baseline
Detailed description:
This is an open label (all people know the identity of the intervention.), multicenter
(study conducted at multiple sites), observational study (individuals are observed for
certain outcomes) of darunavir and etravirine in patients infected with HIV-1 who are naïve
to these medications and who have experienced tolerability issues on their current or prior
combination antiretroviral therapy (medicines used for treatment of HIV). PREZISTA is
indicated for naïve HIV patients (someone who has never used HIV drugs) and
treatment-experienced HIV patients and INTELENCE is indicated for treatment-experienced
patients who have failed prior therapy and have HIV-1 strains resistant to multiple
antiretroviral agents (HIV-1 strains are able to survive the exposure of the multiple
antiretroviral agents), including Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs).
In this study patients will receive either darunavir (PREZISTA) or etravirine (INTELENCE)
and physician selected optimized background agents (other antiretroviral medicines), as
permitted by the local formulary and supported by the current Canadian Product Monograph. 90
patients will participate in this study (75 Patients planned for the darunavir group and 15
patients planned for the etravirine group). The total duration of the study will be 24
weeks. Safety and tolerability will be evaluated at screening (14 days prior to Day 1),
baseline (patient's medical status before any treatment or research is done) at Day 1, Week
4, Week 12 and Week 24. Tolerability will be evaluated using HIV Symptom Distress Module
(HIV-SDM) also referred to as the HIV Symptom Index (HSI) which is a self-completed
questionnaire to evaluate symptoms and measure the presence and bothersomeness of side
effects commonly seen with HIV and antiretroviral treatment over the last 4 weeks (20
questions about all symptoms which the patient might have had during the past four weeks).
Higher scores indicate the presence of more symptoms and/or a greater degree of distress
related to the 20 symptoms. In HIV-SDM data is collected to see the benefit of switching to
either darunavir or etravirine.
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Have a documented HIV-1 infection
- Have 1 or more significant symptoms with at least grade 2 toxicity on the Division of
AIDS Toxicity "DAIDS grading scale" on current or prior combination antiretroviral
therapy (cART) regimen (current or prior cART including regimens consisting of 2
Nucleoside reverse transcriptase inhibitors (NRTIs) and a third agent with the
exception of darunavir or etravirine)
- Have stable response to current cART ie, have an HIV-plasma viral load [number of
virus in blood] at screening <400 copies/mL (undetectable) or last plasma viral load
on prior regimen within the previous 6 months <400 copies/mL)
- Must not have resistance to Primary HIV protease inhibitor medicines
Exclusion Criteria:
- Has been Infected with HIV-2 - Has received previous treatment with darunavir or
etravirine or non-HAART (Highly Active Antiretroviral Therapy) regimen
- Has had prior virologic failure to 2 or more regimens or single virologic failure on
prior cART
- Has a documented resistance to darunavir and etravirine
- Is currently using any drug contraindicated in the current Canadian Product Monograph
for darunavir or etravirine
Locations and Contacts
Vancouver, Canada
Additional Information
Starting date: October 2011
Last updated: May 20, 2014
|